Enclomiphene vs Testosterone: What Trials Compared
A 2025 meta-analysis pooled 10 randomized trials of clomiphene and enclomiphene in male hypogonadism. Here is what it found against placebo and testosterone gel.
If your testosterone is low, there is more than one way to change that number, and the routes are not equivalent in what else they do.
Testosterone replacement supplies the hormone from outside. Selective estrogen receptor modulators, the class that includes clomiphene and enclomiphene, work further upstream: they prompt your own system to produce more. A meta-analysis published in 2025 pooled the randomized evidence comparing these approaches, and the results are worth understanding before a decision, not after.
What was pooled
The review, published in Archives of Endocrinology and Metabolism, combined 10 randomized controlled trials covering 819 participants.
Those participants were spread across treatment arms: 374 on SERM therapy, 133 on testosterone gel, 94 on hCG, 13 on anastrozole, and 205 on placebo. Pooling randomized trials is a stronger form of evidence than any single small study, because it smooths out the noise that individual trials carry.
Against placebo
Compared with placebo, SERM therapy raised all three of the measures you would expect it to.
- Total testosterone: mean difference of 273.76 ng/dL, 95 percent confidence interval 191.87 to 355.66
- LH: mean difference of 4.66 IU/L, confidence interval 3.37 to 5.94
- FSH: mean difference of 4.59 IU/L, confidence interval 2.88 to 6.30
The LH and FSH movement is the mechanistic tell. These are the pituitary signals that instruct the testes to produce testosterone and to support sperm production. Both rising together is what you would see if the hypothalamic pituitary testicular axis were being stimulated rather than replaced.
Against testosterone gel
This is the comparison that changes decisions.
On total testosterone, the two were statistically indistinguishable. The mean difference was 5.41 ng/dL with a confidence interval of negative 43.44 to 54.27, which crosses zero. On the headline number, the trials did not separate them.
On everything else, they separated clearly:
- LH: 7.13 IU/L higher on SERM therapy, confidence interval 5.12 to 9.13
- FSH: 6.98 IU/L higher on SERM therapy, confidence interval 3.04 to 10.93
- Sperm concentration: 70.40 million per mL higher on SERM therapy
That last figure is the one to sit with. Exogenous testosterone suppresses the pituitary signals that drive sperm production, which is a well described effect of supplying the hormone from outside. These head to head trials measured that difference directly.
Two approaches produced a similar testosterone number and did substantially different things to fertility. The headline number was the least informative part of the comparison.
What the authors themselves flag
A meta-analysis is only as good as what went into it, and these authors are direct about the weaknesses.
They report high between-study heterogeneity in testosterone measurements, meaning the individual trials did not all measure the same way or find the same magnitude. They note a potential unit-of-analysis error arising from crossover design studies. And they state that the analyses remain underpowered with regard to safety endpoints.
That last point deserves weight. Underpowered for safety means the pooled data was not large enough to characterize adverse effects reliably. Efficacy signals in this review are considerably firmer than safety conclusions, and reading it as a clean bill of health for either approach would be reading past what the authors wrote.
Where this leaves a decision
It does not make one option correct. It makes the tradeoff legible.
If future fertility is not a consideration for you, the sperm concentration finding may not change anything. If it is, this comparison is directly relevant and worth raising by name.
What this evidence cannot tell you is where your own LH, FSH, and total testosterone actually sit, whether your low testosterone is primary or secondary, which determines whether stimulating the axis is even mechanically plausible for you, or how any of it interacts with the rest of your history. Those come from bloodwork and a provider who reads it with you.
Go in knowing what the trials compared. It makes for a much better conversation.
Common questions
What is the difference between enclomiphene and testosterone replacement?
Testosterone replacement supplies the hormone from outside the body. Enclomiphene is a selective estrogen receptor modulator that acts upstream, raising LH and FSH so the body produces more of its own testosterone. The pooled trials found similar total testosterone between the two approaches but very different effects on the pituitary signals and on sperm concentration.
Does enclomiphene preserve fertility better than testosterone?
In the head to head randomized trials pooled in this 2025 meta-analysis, SERM therapy was associated with sperm concentration 70.40 million per mL higher than testosterone gel, alongside higher LH and FSH. Whether that difference matters for you depends on your goals and your own labs, which is a conversation for a licensed provider.
How strong is this evidence?
It pools 10 randomized controlled trials with 819 participants, which is a reasonably strong design. The authors also state clear limitations: high between-study heterogeneity in testosterone measurement, a possible unit-of-analysis error from crossover trials, and analyses that are underpowered for safety endpoints.
Is enclomiphene FDA approved?
Enclomiphene citrate is not an FDA approved product for treating male hypogonadism. Preparations dispensed through compounding pharmacies are made for an individual patient and are not FDA approved or evaluated for safety and effectiveness. Any decision here belongs with a licensed provider.
Sources
- 1.Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials — Archives of Endocrinology and Metabolism (PMC12510335), 2025
